10 Results for "

type-II diabetes mellitus

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "type-II diabetes mellitus" in MCE Product Catalog:

Cat. No.: HY-177295
CAS No.: 2572566-11-9
Synonyms: LY3549492
Naperiglipron (LY3549492) is an orally active Glucagon-like peptide 1 receptor (GLP-1R) agonist with an EC50 of 1.14 nM for hGLP-1R. Naperiglipron significantly decreases the level of blood glucose in GLP-1R knock-in mouse models. Naperiglipron inhibits PDE10A1 enzyme activity (IC50: 7.43 μM) with a weak hERG inhibitory activity. Naperiglipron can be used for type II diabetes mellitus (T2DM) and obesity research .
loading...
    loading...
Cat. No.: HY-P2501
CAS No.: 135702-23-7
Target:  

Amylin Receptor

Research Areas:  

Metabolic Disease

Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus .
loading...
    loading...
Cat. No.: HY-14810
CAS No.: 647834-15-9
Synonyms: AVE-2268
Target:  

SGLT

Research Areas:  

Metabolic Disease

Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC50s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus .
loading...
    loading...
Cat. No.: HY-154972
Target:  

Glycosidase Amylases

Research Areas:  

Metabolic Disease

α-Amylase/α-Glucosidase-IN-3 (Compound 17) is an α-Amylase/α-Glucosidase dual inhibitor, with IC50s of 0.70 μM and 1.10 μM. α-Amylase/α-Glucosidase-IN-3 can be used for research of type-II diabetes mellitus .
loading...
    loading...
Cat. No.: HY-110178
CAS No.: 1338574-83-6
Purity:  ≥98.0%
Target:  

MAGL

Research Areas:  

Inflammation/Immunology

WWL123, a carbamate-based compound, is a potent and selective ABHD6 inhibitor. WWL123 can be used for research of inflammation, metabolic disorders (obesity and type II diabetes mellitus) and epilepsy .
loading...
    loading...
Cat. No.: HY-160628
CAS No.: 1628641-89-3
Research Areas:  

Metabolic Disease

GPR120 Agonist 4 (example 1) is a GPR120 agonist,with the EC50 values of 1 μM and 0.35 μM for β-arrestin A and Calcium A. GPR120 Agonist 4 can be used for the research of type II diabetes mellitus .
loading...
    loading...
Cat. No.: HY-119534
CAS No.: 555-90-8
Target:  

Glycosidase

Research Areas:  

Metabolic Disease

Nicothiazone is an α-glucosidase inhibitor with a yeast α-glucosidase IC50 of 120.20 μM. Nicothiazone inhibits α-glucosidase enzyme activity. Nicothiazone can be used for the research of type-II diabetes mellitus .
loading...
    loading...
Cat. No.: HY-L040
1,172 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 1,172 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.: HY-171302
CAS No.: 2766799-78-2
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

GLP-1R/GIPR agonist-2 is a GIPR agonist. GLP-1R/GIPR agonist-2 potentiates GIP(1-42)-induced intracellular cAMP production in cells expressing human GIPR. GLP-1R/GIPR agonist-2 can be used for the research of type II diabetes mellitus .
loading...
    loading...
Cat. No.: HY-180489
CAS No.: 3084713-47-0
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

GLP-1R agonist 38 (page 15, compound 1) is a glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R agonist 38 can be used for the study of metabolic disorders and related diseases, including but not limited to type II diabetes mellitus (T2DM), obesity and non-alcoholic fatty liver disease (NASH) .
loading...
    loading...